Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nanobiotix (NBTX) Short term Debt (2018 - 2025)

Nanobiotix has reported Short term Debt over the past 8 years, most recently at $5.0 million for Q4 2025.

  • For Q4 2025, Short term Debt fell 4.67% year-over-year to $5.0 million; the TTM value through Dec 2025 reached $5.0 million, down 4.67%, while the annual FY2025 figure was $5.0 million, 4.67% down from the prior year.
  • Short term Debt for Q4 2025 was $5.0 million at Nanobiotix, down from $5.4 million in the prior quarter.
  • Over five years, Short term Debt peaked at $10.9 million in Q2 2023 and troughed at $4.7 million in Q4 2022.
  • A 5-year average of $6.9 million and a median of $5.4 million in 2023 define the central range for Short term Debt.
  • Biggest five-year swings in Short term Debt: soared 61.57% in 2021 and later tumbled 50.43% in 2022.
  • Year by year, Short term Debt stood at $9.4 million in 2021, then crashed by 50.43% to $4.7 million in 2022, then grew by 16.14% to $5.4 million in 2023, then fell by 2.62% to $5.3 million in 2024, then fell by 4.67% to $5.0 million in 2025.
  • Business Quant data shows Short term Debt for NBTX at $5.0 million in Q4 2025, $5.4 million in Q2 2025, and $5.3 million in Q4 2024.